Disease · MONDO_0100096
Comparisons in its trials839
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 839
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Matched Treated: Long-term Disability vs Matched Untreated: Long-term Disability: Number of Participants With Any Long Term Disability (LTD) Claim: Matched Participants | 50 of 20,318 | 74 of 20,318 | 40,636 | NCT07072793 | Trial comparisons |
| Matched Treated: Short-term Disability vs Matched Untreated: Short-term Disability: Number of Participants With Any Short Term Disability (STD) Claim: Matched Participants | 1,343 of 20,065 | 1,848 of 20,065 | 40,130 | NCT07072793 | Trial comparisons |
| Colchicine vs Placebo: Number of Participants Who Required Mechanical Ventilation in the 30 Days Following Randomization. | 11 of 2,235 | 21 of 2,253 | 4,488 | NCT04322682 | Trial comparisons |
| Colchicine vs Placebo: Number of Deaths in the 30 Days Following Randomization. | 5 of 2,235 | 9 of 2,253 | 4,488 | NCT04322682 | Trial comparisons |
| Colchicine vs Placebo: Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization. | 104 of 2,235 | 131 of 2,253 | 4,488 | NCT04322682 | Trial comparisons |
| Colchicine vs Placebo: Number of Participants Who Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization. | 101 of 2,235 | 128 of 2,253 | 4,488 | NCT04322682 | Trial comparisons |
| Colchicine vs Placebo: deaths from any cause | 5 of 2,195 | 9 of 2,217 | 4,412 | NCT04322682 | Trial comparisons |
| Colchicine vs Placebo: serious adverse events | 108 of 2,195 | 139 of 2,217 | 4,412 | NCT04322682 | Trial comparisons |
| Colchicine vs Placebo: Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization in the Subgroup of Patients With PCR-confirmed COVID-19. | 96 of 2,075 | 126 of 2,084 | 4,159 | NCT04322682 | Trial comparisons |
| Matched Treated: Absence Eligibility vs Matched Untreated: Absence Eligibility: Number of Participants With Presence of Any Absence Records: Matched Participants | 1,255 of 1,909 | 1,331 of 1,909 | 3,818 | NCT07072793 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Emergency Room (ER) Visits for Any Cause | 298 of 2,005 | 155 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Hospitalization for Any Cause | 137 of 2,005 | 123 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants Who Used Invasive Mechanical Ventilation (IMV) | 0 of 2,005 | 1 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Supplemental Oxygen Usage | 21 of 2,005 | 11 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With at Least 1 Pre-existing Comorbidities | 1,709 of 2,005 | 920 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: deaths from any cause | 0 of 2,005 | 0 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Intensive Care Unit (ICU) Admission for Any Cause | 3 of 2,005 | 1 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Arm G - Metformin vs Arm G - Placebo: Number of Participants With Mortality | 0 of 1,443 | 0 of 1,548 | 2,991 | NCT06042855 | Trial comparisons |
| Arm G - Metformin vs Arm G - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death | 54 of 1,443 | 49 of 1,548 | 2,991 | NCT06042855 | Trial comparisons |
| Arm G - Metformin vs Arm G - Placebo: Number of Participants With Hospitalization or Death | 4 of 1,443 | 3 of 1,548 | 2,991 | NCT06042855 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100096/comparisons